Pfizer出售ViiV股价1.88B美元, Shionogi买入,交易关闭Q1 2026。 Pfizer sells its ViiV stake for $1.88B, Shionogi buys in, deal closes Q1 2026.

Pfizer正在退出其合资企业ViiV保健,其11.7%的股息获得18.8亿美元,并因股票被取消而获得2.5亿美元的特别红利。 Pfizer is exiting its joint venture ViiV Healthcare, receiving $1.88 billion for its 11.7% stake and a $250 million special dividend as shares are canceled. 日本的 Shionogi 正在购买新发行的21.3亿美元股份,将股权提高到21.7%,而GSK则保留78.3%的所有权。 Japan’s Shionogi is buying newly issued shares for $2.13 billion, increasing its stake to 21.7%, while GSK retains 78.3% ownership. 这项交易在监管批准之前,预计将在Q1 2026结束,它简化了ViiV的结构,并支持在长期艾滋病毒治疗方面正在进行的合作。 The deal, pending regulatory approval and expected to close in Q1 2026, simplifies ViiV’s structure and supports ongoing collaboration on long-acting HIV treatments. 这笔交易是当辉瑞公司面临疫苗销售下降和专利到期造成的财政压力时进行的,预期到2029年收入不会增长。 The transaction comes as Pfizer faces financial pressures from declining vaccine sales and patent expirations, with no expected revenue growth until 2029. ViiV于2009年由GSK和Pfizer创立,2012年Syonogi加入。 ViiV was founded in 2009 by GSK and Pfizer, with Shionogi joining in 2012.